Compound IX Synthesis Using Palladium Coupling for Higher Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing Compound IX, a key intermediate in the synthesis of Compound A, suffer from low yield and high cost, and often use materials that are not commercially available, impacting the overall cost of synthesizing Compound A, which is used in treating sex hormone diseases.
Innovation Solution
A novel process involving the reaction of Compound I with Compound II in the presence of a palladium catalyst and a base to form Compound III, followed by chlorination, catalytic hydrogenation, and methylation to produce Compound IX with high purity and yield, utilizing commercially available starting materials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing methods are used to produce Compound IX, then the synthesis process can be completed, but the yield is low and the cost is high
Solution Approach 1:
The patent changes the chemical reaction parameters by using a palladium-catalyzed cross-coupling reaction instead of traditional methods. This involves changing the reaction conditions, catalyst system, and starting materials to achieve higher yields and lower costs. Specifically, the use of commercially available starting materials and optimized reaction conditions directly addresses the productivity and cost issues.
Solution Approach 2:
The patent employs commercially available starting materials and catalysts that can be easily obtained and are cost-effective. By using readily available reagents rather than requiring specialized or expensive materials, the process reduces production costs while maintaining high yield, directly resolving the technical contradiction between productivity and ease of manufacture.
2Ease of manufacture
If existing methods are used to produce Compound IX, then the synthesis can proceed, but commercially available materials are not used, impacting overall cost
Solution Approach 1:
The patent uses commercially available starting materials that can serve multiple purposes in the synthesis pathway. The cross-coupling reaction employs universal reagents and catalysts that are widely available in the chemical industry, making the process more accessible and cost-effective. This universality directly improves ease of manufacture while controlling overall costs.
3Manufacturing precision
If traditional synthesis methods are used, then the process is established, but the yield and purity of Compound IX are insufficient for industrial-scale production
Solution Approach 1:
The patent replaces traditional mechanical or conventional chemical methods with a palladium-catalyzed cross-coupling reaction that provides superior control over reaction outcomes. This substitution enables higher purity and yield, making the process suitable for industrial-scale production while maintaining manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves Compound IX with comparable or higher yield and high purity, making it suitable for industrial-scale production of Compound A, which can be used to treat sex hormone diseases.
Implementation Method 1
reacting Compound I with Compound II in the presence of a palladium catalyst and a base to form Compound III
Implementation Method 2
reacting Compound I with Compound II in the presence of a palladium catalyst and a base to form Compound III
Implementation Method 3
catalytic hydrogenation, and methylation to produce Compound IX
Data Source
AI summary
The invention relates to a new process for producing compound 2-(3,5-bis(trifluoromethyl)phenyl)-N-(6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-yl)-N,2-dimethylpropanamide (Compound IX) which is useful in the manufacture of compound 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide (Compound A).